{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-23-001228","form_type":"8-K","ticker":"AXIM","cik":"0001514946","company_name":"AXIM BIOTECHNOLOGIES, INC.","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.187320+00:00","generated_at":"2026-06-14T08:09:49.771215+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AXIM Biotechnologies enters $20M equity purchase agreement with Cross & Company","bullets":["Equity Purchase Agreement for up to $20M of common stock with an institutional investor (Cross & Company).","Company may require investor to buy shares in puts of $10k-$250k, subject to volume limits.","Purchase price set at 87.5% of lowest traded price during a 10-day valuation period after clearing.","Agreement term up to 3 years; registration statement on Form S-1 required for resale of put shares.","Issuance capped at 4.99% beneficial ownership; dilution potential from discounted share sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-23-001228","json":"https://secwatch.observer/filing/0001096906-23-001228.json","markdown":"https://secwatch.observer/filing/0001096906-23-001228.md","text":"https://secwatch.observer/filing/0001096906-23-001228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/0001096906-23-001228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/axim-20230601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T08:09:49.771215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07f32c2bfdfa11f9058efcac01bb4dbc01497d10","claim":"AXIM BIOTECHNOLOGIES, INC. entered into Equity Purchase Agreement with an institutional accredited investor (the \"Investor\") valued at up to $20,000,000 (effective 2023-06-01).","evidence_excerpt":"On June 1, 2023, AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”), pursuant to which the Investor committed to purchase up to $20,000,000 of the Company’s common stock (the “Financing”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/0001096906-23-001228-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional accredited investor (the \"Investor\")"},{"label":"Value","value":"up to $20,000,000"},{"label":"Effective","value":"2023-06-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}